PMID- 16817981
OWN - NLM
STAT- MEDLINE
DCOM- 20070416
LR  - 20161020
IS  - 1461-1457 (Print)
IS  - 1461-1457 (Linking)
VI  - 10
IP  - 2
DP  - 2007 Apr
TI  - A preliminary open-label study of 5-HT1A partial agonist tandospirone for 
      behavioural and psychological symptoms associated with dementia.
PG  - 281-3
AB  - The aim of this study was to assess the efficacy and safety of tandospirone, a 
      5-HT1A partial agonist, for treatment of behavioural and psychological symptoms 
      of dementia (BPSD). Thirteen outpatients with DSM-IV diagnosis of Alzheimer's 
      type or vascular dementia were enrolled in this study. Their BPSD and cognitive 
      functions were evaluated with the Neuropsychiatric Inventory (NPI) and 
      Mini-Mental State Examination, respectively, for an 8-wk period of treatment. The 
      maximum benefit of tandospirone was achieved at a mean dose of 19.6 mg/d. There 
      were significant improvements in the NPI subscores for delusion, agitation, 
      depression, anxiety, and irritability at 2 or 4 wk after the start of 
      administration of tandospirone. No patients experienced severe adverse effects. 
      The results suggest that tandospirone was effective at improving BPSD symptoms 
      and well-tolerated in elderly demented patients.
FAU - Sato, Shinji
AU  - Sato S
AD  - Department of Psychiatry, Tsukuba Memorial Hospital, Tsukuba, Japan.
FAU - Mizukami, Katsuyoshi
AU  - Mizukami K
FAU - Asada, Takashi
AU  - Asada T
LA  - eng
PT  - Clinical Trial
PT  - Journal Article
DEP - 20060703
PL  - England
TA  - Int J Neuropsychopharmacol
JT  - The international journal of neuropsychopharmacology
JID - 9815893
RN  - 0 (Isoindoles)
RN  - 0 (Piperazines)
RN  - 0 (Pyrimidines)
RN  - 0 (Serotonin Receptor Agonists)
RN  - 112692-38-3 (Receptor, Serotonin, 5-HT1A)
RN  - 190230I669 (tandospirone)
SB  - IM
MH  - Aged
MH  - Aged, 80 and over
MH  - Alzheimer Disease/drug therapy/psychology
MH  - Behavior/drug effects
MH  - Dementia/*drug therapy/*psychology
MH  - Dementia, Vascular/drug therapy/psychology
MH  - Dose-Response Relationship, Drug
MH  - Female
MH  - Humans
MH  - Isoindoles
MH  - Male
MH  - Neuropsychological Tests
MH  - Pilot Projects
MH  - Piperazines/adverse effects/*therapeutic use
MH  - Psychiatric Status Rating Scales
MH  - Pyrimidines/adverse effects/*therapeutic use
MH  - Receptor, Serotonin, 5-HT1A/*drug effects
MH  - Serotonin Receptor Agonists/adverse effects/*therapeutic use
EDAT- 2006/07/05 09:00
MHDA- 2007/04/17 09:00
CRDT- 2006/07/05 09:00
PHST- 2006/03/23 00:00 [received]
PHST- 2006/05/09 00:00 [revised]
PHST- 2006/05/13 00:00 [accepted]
PHST- 2006/07/05 09:00 [pubmed]
PHST- 2007/04/17 09:00 [medline]
PHST- 2006/07/05 09:00 [entrez]
AID - S1461145706007000 [pii]
AID - 10.1017/S1461145706007000 [doi]
PST - ppublish
SO  - Int J Neuropsychopharmacol. 2007 Apr;10(2):281-3. doi: 10.1017/S1461145706007000. 
      Epub 2006 Jul 3.